Phase III Gazyva Trial Fails to Meet Primary Endpoint of Improving PFS in DLBCL

Letai shares weekly musings in NCI’s new “Tuesdays with Tony” series

This summer, NCI launched a weekly social media series hosted by Director Anthony Letai.

September 18, 2026

Blood cancer patients may have broader stem cell donor options than previously thought, ACCESS trial shows

Blood cancer patients who cannot find a closely matched stem cell donor may have more transplant options than previously thought.

September 11, 2026

Vol.52 No.33

Drugs & Targets

FDA approves first-of-its-kind drug rusfertide for polycythemia vera

FDA approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells. The excess cells can thicken the blood and increase the risk of cardiovascular issues, such as blood clots, stroke and heart attack.

September 11, 2026

Vol.52 No.33

Clinical Roundup

SANRECO phase II study of divesiran in polycythemia vera meets primary endpoint

The SANRECO phase II trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera, met its primary endpoint and secondary endpoints. The 36-week, randomized, double-blind, placebo-controlled portion of the trial administered divesiran subcutaneously (6 mg/kg) every six weeks or every twelve weeks.

August 14, 2026

Vol.52 No.32

Clinical Roundup

BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds

A team of investigators have uncovered a rare genetic mutation that enables some blood cancers to evade both approved Bruton tyrosine kinase inhibitors and newer BTK degraders.

July 31, 2026

Vol.52 No.30

Clinical Trials & Tribulations

Saving Western Kenya’s pediatric blood cancer patients
How flow cytometry is changing the diagnostic landscape

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced.

July 10, 2026

Vol.52 No.27

By Samuel (Tony) Boova, Eda Holl, LaToya Montgomery, Steve Kussick, Nicholas Kigen, Gilbert Olbara, Festus Muigai Njuguna, Terry Vik and Teresa Loile Lotodo

Phase III Gazyva Trial Fails to Meet Primary Endpoint of Improving PFS in DLBCL

YOU MAY BE INTERESTED IN

Letai shares weekly musings in NCI’s new “Tuesdays with Tony” series

Blood cancer patients may have broader stem cell donor options than previously thought, ACCESS trial shows

FDA approves first-of-its-kind drug rusfertide for polycythemia vera

SANRECO phase II study of divesiran in polycythemia vera meets primary endpoint

BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds

Saving Western Kenya’s pediatric blood cancer patients
How flow cytometry is changing the diagnostic landscape

Renew today!

Subscriber content

Never miss an issue!

Login

Phase III Gazyva Trial Fails to Meet Primary Endpoint of Improving PFS in DLBCL

YOU MAY BE INTERESTED IN

Letai shares weekly musings in NCI’s new “Tuesdays with Tony” series

Blood cancer patients may have broader stem cell donor options than previously thought, ACCESS trial shows

FDA approves first-of-its-kind drug rusfertide for polycythemia vera

SANRECO phase II study of divesiran in polycythemia vera meets primary endpoint

BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds

Saving Western Kenya’s pediatric blood cancer patientsHow flow cytometry is changing the diagnostic landscape

Never miss an issue!

Login

Saving Western Kenya’s pediatric blood cancer patients
How flow cytometry is changing the diagnostic landscape